Sarepta Therapeutics Inc. (SRPT)

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Sarepta business and prospects, resulting in its stock trading at inflated prices.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2025 that were previously app...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Sarepta Therapeutics, I...

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Sarepta business and prospects, resulting in its stock trading at inflated prices.

Over the past year, Editas Medicine (EDIT -3.20%) and Sarepta Therapeutics (SRPT -1.38%), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatili...

LOS ANGELES--(BUSINESS WIRE)---- $SRPT--SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

The Food and Drug Administration (FDA) on Tuesday said it is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Sarepta Therapeutics, I...

Sarepta stock dropped again Wednesday after the FDA announced it's investigating the deaths of two patients who received Elevidys.

The U.S. Food and Drug Administration said on Tuesday that it is investigating reports of two deaths due to acute liver failure in non-ambulatory Duchenne muscular dystrophy patients after receiving S...

Earlier this week, Sarepta Therapeutics, Inc SRPT provided a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dy...